Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Graves' Disease Forecast in 23 Major Markets 2017-2027 - Research and Markets

Research and Markets
Posted on: 03 Oct 17

The "Graves' Disease Forecast in 23 Major Markets 2017-2027" report has been added to Research and Markets' offering.

Graves' disease is an autoimmune disease of the thyroid gland, in which the thyroid attacked by the body's own defence mechanisms becomes enlarged and produces increased amount of hormones, causing hyperthyroidism. The condition induces signs and symptoms that seriously affect the patient's quality of life, everyday activities and ability to work.

This report provides the current prevalent population for Graves' disease across 23 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, The Netherlands, Norway, Sweden, Austria, Denmark, Iceland, Switzerland, Turkey, Japan, China, South Korea, India, Australia, Brazil, Mexico) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team, several of the main symptoms and co-morbidities of Graves' disease have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

The quantified symptoms and co-morbidities for Graves' disease include:

  • Graves' Ophthalmopathy
  • Acropachy
  • Thyroid dermopathy

Key Topics Covered:

1. Introduction

2. Cause of the Disease

3. Risk Factors & Prevention

4. Diagnosis of the Disease

5. Variation by Geography/Ethnicity

6. Disease Prognosis & Clinical Course

7. Key Comorbid Conditions / Features Associated With the Disease

8. Methodology for Quantification of Patient Numbers

9. Top-Line Prevalence for Graves' Disease

10. Features of Graves' Disease Patients

11. Comorbid Conditions of Graves' Disease Patients

12. Abbreviations Used in the Report

13. Other Publications

14. Patient-Based Databases

15. Patient-Based Offering

16. Online Pricing Data & Platforms

17. References

18. Appendix

For more information about this report visit

View source version on

Business Wire

Last updated on: 03/10/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.